The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients

Chih Chiang Chiu, Kun Po Chen, Hui Ching Liu, Mong Liang Lu

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Recently, increasing attention has been drawn to the potential diabetogenic effect of atypical antipsychotics. The goal of this prospective study is to evaluate the early effect of olanzapine and risperidone treatment on pancreatic β-cell function in atypical-naive schizophrenic patients. Twenty-six subjects were assigned randomly to therapy with olanzapine or risperidone for 14 days. The metabolic parameters were quantitatively assessed by using the intravenous glucose tolerance test. The levels of fasting glucose, fasting insulin, lipid profiles, and leptin were also assessed. There were no significant within-group changes in weight or body mass index for both groups after 2 weeks of treatment. The levels of fasting glucose, fasting insulin, cholesterol, or leptin did not change in both groups. The triglyceride level significantly increased in olanzapine group. Glucose disappearance rate and insulin sensitivity did not change in both groups. Insulin secretion significantly decreased in olanzapine group. After 2 weeks of olanzapine treatment, schizophrenic patients decreased insulin secretory response to a hyperglycemic challenge. The results of this study support the hypothesis that olanzapine might directly impair pancreatic β-cell function.

Original languageEnglish
Pages (from-to)504-507
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume26
Issue number5
DOIs
Publication statusPublished - Oct 2006

Fingerprint

olanzapine
Risperidone
Insulin
Fasting
Leptin
Glucose
Therapeutics
Glucose Tolerance Test
Antipsychotic Agents
Insulin Resistance
Triglycerides
Body Mass Index
Cholesterol
Prospective Studies
Lipids
Weights and Measures

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. / Chiu, Chih Chiang; Chen, Kun Po; Liu, Hui Ching; Lu, Mong Liang.

In: Journal of Clinical Psychopharmacology, Vol. 26, No. 5, 10.2006, p. 504-507.

Research output: Contribution to journalArticle

@article{479e41093fa04f52a32868598f446333,
title = "The early effect of olanzapine and risperidone on insulin secretion in atypical-na{\"i}ve schizophrenic patients",
abstract = "Recently, increasing attention has been drawn to the potential diabetogenic effect of atypical antipsychotics. The goal of this prospective study is to evaluate the early effect of olanzapine and risperidone treatment on pancreatic β-cell function in atypical-naive schizophrenic patients. Twenty-six subjects were assigned randomly to therapy with olanzapine or risperidone for 14 days. The metabolic parameters were quantitatively assessed by using the intravenous glucose tolerance test. The levels of fasting glucose, fasting insulin, lipid profiles, and leptin were also assessed. There were no significant within-group changes in weight or body mass index for both groups after 2 weeks of treatment. The levels of fasting glucose, fasting insulin, cholesterol, or leptin did not change in both groups. The triglyceride level significantly increased in olanzapine group. Glucose disappearance rate and insulin sensitivity did not change in both groups. Insulin secretion significantly decreased in olanzapine group. After 2 weeks of olanzapine treatment, schizophrenic patients decreased insulin secretory response to a hyperglycemic challenge. The results of this study support the hypothesis that olanzapine might directly impair pancreatic β-cell function.",
author = "Chiu, {Chih Chiang} and Chen, {Kun Po} and Liu, {Hui Ching} and Lu, {Mong Liang}",
year = "2006",
month = "10",
doi = "10.1097/01.jcp.0000237947.80764.d9",
language = "English",
volume = "26",
pages = "504--507",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients

AU - Chiu, Chih Chiang

AU - Chen, Kun Po

AU - Liu, Hui Ching

AU - Lu, Mong Liang

PY - 2006/10

Y1 - 2006/10

N2 - Recently, increasing attention has been drawn to the potential diabetogenic effect of atypical antipsychotics. The goal of this prospective study is to evaluate the early effect of olanzapine and risperidone treatment on pancreatic β-cell function in atypical-naive schizophrenic patients. Twenty-six subjects were assigned randomly to therapy with olanzapine or risperidone for 14 days. The metabolic parameters were quantitatively assessed by using the intravenous glucose tolerance test. The levels of fasting glucose, fasting insulin, lipid profiles, and leptin were also assessed. There were no significant within-group changes in weight or body mass index for both groups after 2 weeks of treatment. The levels of fasting glucose, fasting insulin, cholesterol, or leptin did not change in both groups. The triglyceride level significantly increased in olanzapine group. Glucose disappearance rate and insulin sensitivity did not change in both groups. Insulin secretion significantly decreased in olanzapine group. After 2 weeks of olanzapine treatment, schizophrenic patients decreased insulin secretory response to a hyperglycemic challenge. The results of this study support the hypothesis that olanzapine might directly impair pancreatic β-cell function.

AB - Recently, increasing attention has been drawn to the potential diabetogenic effect of atypical antipsychotics. The goal of this prospective study is to evaluate the early effect of olanzapine and risperidone treatment on pancreatic β-cell function in atypical-naive schizophrenic patients. Twenty-six subjects were assigned randomly to therapy with olanzapine or risperidone for 14 days. The metabolic parameters were quantitatively assessed by using the intravenous glucose tolerance test. The levels of fasting glucose, fasting insulin, lipid profiles, and leptin were also assessed. There were no significant within-group changes in weight or body mass index for both groups after 2 weeks of treatment. The levels of fasting glucose, fasting insulin, cholesterol, or leptin did not change in both groups. The triglyceride level significantly increased in olanzapine group. Glucose disappearance rate and insulin sensitivity did not change in both groups. Insulin secretion significantly decreased in olanzapine group. After 2 weeks of olanzapine treatment, schizophrenic patients decreased insulin secretory response to a hyperglycemic challenge. The results of this study support the hypothesis that olanzapine might directly impair pancreatic β-cell function.

UR - http://www.scopus.com/inward/record.url?scp=33748749787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748749787&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000237947.80764.d9

DO - 10.1097/01.jcp.0000237947.80764.d9

M3 - Article

C2 - 16974193

AN - SCOPUS:33748749787

VL - 26

SP - 504

EP - 507

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -